# Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention

> **NCT02430259** · PHASE3 · COMPLETED · sponsor: **Huashan Hospital** · enrollment: 566 (estimated)

## Conditions studied

- Silicosis
- Tuberculosis

## Interventions

- **DRUG:** Weekly INH / RRT given by DOT

## Key facts

- **NCT ID:** NCT02430259
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 566 (ESTIMATED)
- **Last updated:** 2020-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02430259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02430259, "Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02430259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*